Covance announced the introduction of Covance MarketPlace, a new solution that enables Covance?s emerging biotechnology and established pharmaceutical clients to find and forge new partnerships in a secure forum.
Covance announced the introduction of Covance MarketPlace, a new solution that enables Covance’s emerging biotechnology and established pharmaceutical clients to find and forge new partnerships in a secure forum.
Sourcing high-quality drug candidates efficiently and effectively is a pivotal step in the industry’s quest to accelerate the development and launch of innovative new medicines. Covance MarketPlace helps biotech more effectively showcase their molecules to larger pharmaceutical companies as they continue to increase their own in-licensing efforts.
The company is actively working with its client base of more than 500 biotechnology companies to place their compounds into Covance MarketPlace. Upon completion, Covance MarketPlace will be activated for select Covance pharmaceutical clients, giving them line-of-sight to molecules early in their development lifecycle, typically at the IND/CTA-enabling, first-in-human or proof-of- concept phase.
“With expertise from pre-clinical through market commercialization, Covance can proactively guide our clients in the design of programs that link robust preclinical strategies to optimized clinical plans to improved product labels,” said Steve Street, Vice President and General Manager of Covance Early Development. “This scientific, medical and regulatory continuity combined with our unique understanding of the challenges faced by emerging biotechnology companies, affords us tremendous insights that we use to streamline a molecule’s development. Helping our biotechnology clients enhance the quality and value of their compounds while gaining vital exposure to the right audiences at the right time can increase the likelihood of a novel medicine advancing into the clinic and, ultimately, to patients.”
Read here for the complete press release.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
March 27th 2024Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.